Treatment of the PC-3 prostate cancer cell line, which has activated PI3K/AKT signaling due to homozygous loss of the tumor suppressor PTEN, with the allosteric AKT inhibitor, MK-2206, causes these cells to stiffen [93]. The gene discussed is AKT1; the disease is prostate carcinoma.